Collaboration Aims to Enhance Cardiac Gene Therapy Delivery

January 8, 2026 - 23:52

Lexeo Therapeutics is collaborating with Johnson & Johnson's unit Abiomed to explore the use of the Impella heart pump technology for delivering cardiac gene therapies. This partnership aims to leverage the innovative capabilities of the Impella device, which is designed to support heart function by providing temporary mechanical assistance to patients with severe heart conditions.

The focus of this collaboration is to develop a potentially safer and more effective method for administering genetic medicines directly to the heart. By utilizing the Impella technology, the team hopes to overcome some of the challenges associated with traditional delivery methods, which can be invasive and carry significant risks.

This initiative highlights the growing interest in gene therapy as a transformative approach to treating various cardiovascular diseases. As both companies work together, they aim to advance the field of cardiac medicine and improve patient outcomes through innovative delivery solutions. The partnership represents a significant step forward in the quest for more effective treatments for heart-related ailments.